Cytokinetics, Incorporated $CYTK Position Decreased by FNY Investment Advisers LLC

FNY Investment Advisers LLC lowered its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 77.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,000 shares of the biopharmaceutical company’s stock after selling 7,030 shares during the period. FNY Investment Advisers LLC’s holdings in Cytokinetics were worth $170,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its stake in Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Cytokinetics in the fourth quarter valued at $27,000. Kestra Advisory Services LLC bought a new position in shares of Cytokinetics in the fourth quarter valued at $29,000. Quarry LP acquired a new stake in shares of Cytokinetics during the 3rd quarter valued at $30,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Cytokinetics during the 4th quarter valued at $32,000.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $76.76 on Friday. Cytokinetics, Incorporated has a twelve month low of $32.89 and a twelve month high of $88.31. The stock has a market cap of $9.55 billion, a price-to-earnings ratio of -10.63 and a beta of 0.38. The firm’s 50 day moving average price is $78.91 and its two-hundred day moving average price is $70.90.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. Cytokinetics’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.12) EPS. On average, research analysts forecast that Cytokinetics, Incorporated will post -6.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CYTK has been the topic of a number of recent research reports. Royal Bank Of Canada decreased their target price on Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a report on Friday. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and increased their price target for the company from $69.00 to $115.00 in a research report on Monday, June 29th. Truist Financial set a $106.00 price target on Cytokinetics in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytokinetics in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $100.85.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Insider Activity

In related news, EVP Andrew Callos sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the transaction, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,337,754.40. The trade was a 20.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $84.92, for a total value of $636,900.00. Following the completion of the sale, the chief executive officer directly owned 377,830 shares of the company’s stock, valued at approximately $32,085,323.60. This represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 115,179 shares of company stock worth $9,126,054. 2.60% of the stock is owned by corporate insiders.

About Cytokinetics

Cytokinetics, Inc is a late?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.